Literature DB >> 15039315

Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.

Amit Chattopadhyay1, Laurie R Gray, Lauren L Patton, Daniel J Caplan, Gary D Slade, Hsaio-Chuan Tien, Diane C Shugars.   

Abstract

Oropharyngeal candidiasis, typically caused by Candida albicans, is the most common oral disease associated with human immunodeficiency virus type 1 (HIV-1) infection. Secretory leukocyte protease inhibitor (SLPI), a 12-kDa antiprotease, suppresses the growth of C. albicans in vitro. To determine whether the mucosal protein plays a role in protecting oral tissues against fungal infection, we conducted a cross-sectional study investigating the oral and systemic health and salivary SLPI levels in 91 dentate HIV-1-infected adults receiving medical care in the southeastern United States. Participants with a self-reported history of clinical oropharyngeal candidiasis during the previous 2 years constituted the test group (n = 52), while the comparison group (n = 39) had no oropharyngeal candidiasis during that period. Data collected from medical records, oral examination, and SLPI enzyme-linked immunosorbent assay quantitation of whole saliva were analyzed by t test, analysis of variance, linear regression, and unconditional logistic regression. The test group had a significantly higher mean salivary SLPI level than the comparison group (1.9 microg/ml versus 1.1 microg/ml, P < 0.05). Linear regression modeling identified CD4 cell count and history of oropharyngeal candidiasis as key predictors of salivary SLPI and revealed a significant interaction (P < 0.05) between immunosuppression (CD4 cell count below 200 cells/ microl) and positive history of oropharyngeal candidiasis in predicting salivary SLPI level. By logistic regression modeling, a salivary SLPI level exceeding 2.1 microg/ml, low CD4 count, antiretroviral monotherapy, and smoking were key predictors of oropharyngeal candidiasis. These data support a key role for SLPI in the oral mucosal defense against C. albicans. The antimicrobial mucosal protein may serve as an indicator of previous oropharyngeal candidiasis infection among immunosuppressed persons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039315      PMCID: PMC375171          DOI: 10.1128/IAI.72.4.1956-1963.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load.

Authors:  L L Patton; R G McKaig; J J Eron; H P Lawrence; R P Strauss
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

Review 2.  Antimicrobial peptides: therapeutic potential for the treatment of Candida infections.

Authors:  Antonella Lupetti; Romano Danesi; Jan W van 't Wout; Jaap T van Dissel; Sonia Senesi; Peter H Nibbering
Journal:  Expert Opin Investig Drugs       Date:  2002-02       Impact factor: 6.206

3.  Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress.

Authors:  E Cavarra; M Lucattelli; F Gambelli; B Bartalesi; S Fineschi; A Szarka; F Giannerini; P A Martorana; G Lungarella
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-08       Impact factor: 5.464

4.  Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.

Authors:  Curtis P Bradney; Gregory D Sempowski; Hua-Xin Liao; Barton F Haynes; Herman F Staats
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  A comprehensive study of Candida-specific antibodies in the saliva of human immunodeficiency virus-positive individuals with oropharyngeal candidiasis.

Authors:  Karen L Wozniak; Janet E Leigh; Shannon Hager; Rolf K Swoboda; Paul L Fidel
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

6.  Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.

Authors:  H Hocini; P Becquart; H Bouhlal; H Adle-Biassette; M D Kazatchkine; L Bélec
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

Review 7.  Endogenous salivary inhibitors of human immunodeficiency virus.

Authors:  D C Shugars; A L Alexander; K Fu; S A Freel
Journal:  Arch Oral Biol       Date:  1999-06       Impact factor: 2.633

8.  Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS).

Authors:  D Greenspan; E Komaroff; M Redford; J A Phelan; M Navazesh; M E Alves; H Kamrath; R Mulligan; C E Barr; J S Greenspan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-09-01       Impact factor: 3.731

9.  Candidal carriage in the oral cavity of human immunodeficiency virus-infected subjects.

Authors:  Giuseppina Campisi; Giuseppe Pizzo; Maria E Milici; Salvatrice Mancuso; Valerio Margiotta
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2002-03

10.  Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing.

Authors:  G S Ashcroft; K Lei; W Jin; G Longenecker; A B Kulkarni; T Greenwell-Wild; H Hale-Donze; G McGrady; X Y Song; S M Wahl
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

View more
  18 in total

Review 1.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome.

Authors:  H R Conti; O Baker; A F Freeman; W S Jang; S M Holland; R A Li; M Edgerton; S L Gaffen
Journal:  Mucosal Immunol       Date:  2011-02-23       Impact factor: 7.313

3.  Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations.

Authors:  S Rahman; C M Pierce Campbell; B N Torres; M T O'Keefe; D J Ingles; L L Villa; R J Carvalho da Silva; R C Cintra; E Lazcano-Ponce; J Salmeron; M Quiterio; A R Giuliano
Journal:  Oral Dis       Date:  2016-08-17       Impact factor: 3.511

4.  Systemic and mucosal differences in HIV burden, immune, and therapeutic responses.

Authors:  Sharon M Wahl; Maryann Redford; Shawna Christensen; Wendy Mack; Jon Cohn; Edward N Janoff; Jiri Mestecky; Hal B Jenson; Mahvash Navazesh; Mardge Cohen; Patricia Reichelderfer; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

Review 5.  Fungal proteases and their pathophysiological effects.

Authors:  Iwona Yike
Journal:  Mycopathologia       Date:  2011-01-23       Impact factor: 2.574

6.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

7.  Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Authors:  Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 8.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

9.  Smoking as a risk factor for oral candidiasis in HIV-infected adults.

Authors:  Amit Chattopadhyay; Lauren L Patton
Journal:  J Oral Pathol Med       Date:  2012-12-04       Impact factor: 4.253

10.  Aberrant host defense against Leishmania major in the absence of SLPI.

Authors:  Nancy McCartney-Francis; Wenwen Jin; Yasmine Belkaid; George McGrady; Sharon M Wahl
Journal:  J Leukoc Biol       Date:  2014-07-16       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.